Abstract: Compounds having a mimetic or antagonistic property of an inositol phosphoglycan, and the uses of these compounds are disclosed, together with the use, e.g. to treat a condition ameliorated by administration of an IPG second messenger or an IPG antagonist thereof. In particular, the compounds are based on the 1,6 linkage of a sugar residue and a cyclitol.

Abstract: Compounds having a mimetic or antagonistic property of an inositol phosphoglycan, and the uses of these compounds are disclosed, together with the use, e.g. to treat a condition ameliorated by administration of an IPG second messenger or an IPG antagonist thereof. In particular, the compounds are based on the 1,6 linkage of a sugar residue and a cyclitol.

Abstract: Compounds having a mimetic or antagonistic property of an inositol phosphoglycan, and the uses of these compounds are disclosed, together with the use, e.g. to treat a condition ameliorated by administration of an IPG second messenger or an IPG antagonist thereof. Preferred compounds of the invention are based on the substituted cyclitols, such as the chiro-inositol derivative pinitol (3-O-methyl-chiro-inositol).

Abstract: The present invention relates to anti-IPG antibodies, and in particular monoclonal antibodies produced by hybridoma cell lines 2F7. 2D1 and 5H6, and the use of these and other similar antibodies in the treatment and diagnosis of pre-eclampsia or diabetes, especially type I diabetes. A method of producing anti-IPG antibodies by immunising an animal with IPG unconjugated to an immunogenic carrier is also disclosed.

Abstract: Compounds having a mimetic or antagonistic property of an inositol phosphoglycan, and the uses of these compounds are disclosed, together with the use, e.g. to treat a condition ameliorated by administration of an IPG second messenger or an IPG antagonist thereof. Preferred compounds of the invention are based on the substituted cyclitols, and in particular, the compounds are based on the 1,6 linkage of two or more sugar residues to a cyclitol.

Abstract: The diagnosis of diabetes based on the level or ratio of P- and A-type inositolphosphoglycans (IPGs) in a sample from a patient is disclosed.

Abstract: The diagnosis of diabetes based on the level or ratio of P- and A-type inositolphosphoglycans (IPGs) in a sample from a patient, and the use of P- and A-type IPGs or their antagonists in the treatment of diabetes is disclosed. In particular, the present invention provides treatment of IDDM or lean type II diabetes (NIDDM) with a mixture of P- and A-type mediators, and treatment of obese type II diabetes (NIDDM) with a P-type mediator and/or an A-type antagonist.

Abstract: The application relates to the purification and characterisation of a family of P-type inositolphosphoglycans (IPGs) from human liver and placenta. These substances are shown to have P-type biological activity, e.g. activating pyruvate dehydrogenase (PDH) phosphatase. The characterisation of the compounds demonstrates that they contain metal ions, in particular Mn2+ and/or Zn2+, and optionally phosphate. The compounds and their antagonists have uses as pharmaceuticals, e.g. for the treatment of diabetes, and in screening for synthetic analogues.

Abstract: The present invention relates to materials and methods for the diagnosis and treatment of pre-eclampsia, and more particularly to the role of P-type inositolphosphoglycans (IPGs) in the occurrence of pre-eclampsia. Methods of diagnosing pre-eclampsia by determining the level of P-type IPGs and uses of antagonists of P-type IPGs in the treatment of pre-eclampsia are disclosed, together with a method for screening for P-type IPG antagonists.

Abstract: The present invention relates to materials and methods for the diagnosis and treatment of pre-eclampsia, and more particularly to the role of P-type inositolphosphoglycans (IPGs) in the occurrence of pre-eclampsia. Methods of diagnosing pre-eclampsia by determining the level of P-type IPGs and uses of antagonists of P-type IPGs in the treatment of pre-eclampsia are disclosed, together with a method for screening for P-type IPG antagonists.